ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Cycloastragenol overcomes trastuzumab resistance in HER2-positive breast cancer by regulating cell cycle and epithelial-mesenchymal transition through EZH2/PTEN/AKT pathway.
Mingyuan Wu et al.PubMed ↗Publisher ↗
No numbers read from the abstract.